# Cipla Limited, Pithampur, District Dhar, India – FDA Inspections

Source: https://www.keypedia.com/companies/cipla-limited/de9dc5de-fbea-4a7d-ab5b-a398b6ed442e

> Inspection records and compliance data for Cipla Limited in Pithampur, District Dhar. 9 FDA inspections on record (1 OAI), 4 Form 483s, 2 warning letters, last inspected August 25, 2026.

---

## Details

- Name: Cipla Limited
- FEI Number: 3008581988
- Business Operations: FDF MANUFACTURE
- Address Line 1: Plot No. 9 & 10, Pharma Zone Phase Ii, Section Iiii, Indore Special Economic Zone
- City: Pithampur, District Dhar
- Country Name: India
- Address: Plot No. 9 & 10, Pharma Zone Phase Ii, Section Iiii, Indore Special Economic Zone, Pithampur, District Dhar, India
- Country: India

## Related Documents

- [483 - Cipla Limited - 2026-08-25](https://www.keypedia.com/records/483/cipla-limited/a0856369-8345-48b9-a3e3-cb2657ac1116) — source: FDA, date: August 25, 2026
- [FDA Inspection 1331746 - Cipla Limited - 2026-08-25](https://www.keypedia.com/records/fda_inspections/cipla-limited/8e984a05-d69e-4ebb-beb1-b0eca787a4ba) — source: FDA, date: August 25, 2026
- [483 - Cipla Limited - 2023-02-17](https://www.keypedia.com/records/483/cipla-limited/0c4d85ed-d21a-4440-8835-7e2f111667e9) — source: FDA, date: February 17, 2023
- [WARNING_LETTER - Cipla Limited - 2023-02-17](https://www.keypedia.com/records/warning_letter/cipla-limited/4a179ebd-255d-4805-a6d2-4e500633be4e) — source: FDA, date: February 17, 2023
- [FDA Inspection 1198343 - Cipla Limited - 2023-02-17](https://www.keypedia.com/records/fda_inspections/cipla-limited/69b7c844-7159-454b-b581-1a728cf834a1) — classification: Official Action Indicated (OAI), source: FDA, date: February 17, 2023
- [483 - Cipla Limited - 2022-07-01](https://www.keypedia.com/records/483/cipla-limited/606c0e82-5b62-4d28-bbe3-aa7eac7ea30d) — source: FDA, date: July 1, 2022
- [WARNING_LETTER - Cipla Limited - 2019-09-27](https://www.keypedia.com/records/warning_letter/cipla-limited/6321f828-da26-4571-b32c-638dd2cf14df) — source: FDA, date: September 27, 2019
- FDA Inspection 1094880 - Cipla Limited - 2019-05-17 — classification: No Action Indicated (NAI), source: FDA, date: May 17, 2019
- [483 - Cipla Limited - 2018-04-13](https://www.keypedia.com/records/483/cipla-limited/c8ec2a41-eca9-41c6-8e7d-d507b965a6dc) — source: FDA, date: April 13, 2018
- [FDA Inspection 1048005 - Cipla Limited - 2018-04-13](https://www.keypedia.com/records/fda_inspections/cipla-limited/e8143ba3-08be-4081-940c-dd76d60ee6da) — classification: Voluntary Action Indicated (VAI), source: FDA, date: April 13, 2018
- [FDA Inspection 1019068 - Cipla Limited - 2017-06-23](https://www.keypedia.com/records/fda_inspections/cipla-limited/8d1e8e30-55f5-46d8-9263-32aedd2aef4f) — source: FDA, date: June 23, 2017
- FDA Inspection 1019068 - Cipla Limited - 2017-06-23 — source: FDA, date: June 23, 2017
- FDA Inspection 1007876 - Cipla Limited - 2017-01-27 — source: FDA, date: January 27, 2017
- FDA Inspection 940719 - Cipla Limited - 2015-08-07 — classification: Voluntary Action Indicated (VAI), source: FDA, date: August 7, 2015
- FDA Inspection 821114 - Cipla Limited - 2013-03-01 — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 1, 2013
- [FDA Inspection 806838 - Cipla Limited - 2012-11-02](https://www.keypedia.com/records/fda_inspections/cipla-limited/78379ee7-9bf8-4cc2-977e-c2560781fac2) — classification: No Action Indicated (NAI), source: FDA, date: November 2, 2012

## Related Companies

- [Mylan Laboratories Limited](https://www.keypedia.com/companies/mylan-laboratories-limited/4fd10a2e-3696-4bd0-82aa-e875143028c0)
- [Ipca Laboratories Limited](https://www.keypedia.com/companies/ipca-laboratories-limited/4221e8f5-a261-45fc-b9fc-d935bc1f225b)
- [Pfizer Healthcare India Private Limited](https://www.keypedia.com/companies/pfizer-healthcare-india-private-limited/50c6f34f-3ef8-4cd6-bd55-6e1ee280d4f7)
- [Glenmark Pharmaceuticals Limited](https://www.keypedia.com/companies/glenmark-pharmaceuticals-limited/66c964bb-f670-493b-ab86-aa8507e68a5d)
- [NATCO Pharma Limited](https://www.keypedia.com/companies/natco-pharma-limited/4c97e2d8-0023-4572-966f-d396e8fecc05)
- [Genentech, Inc.](https://www.keypedia.com/companies/genentech-inc/97918967-ab2f-4019-9954-a0d687852d27)
- [MSD International GmbH (Puerto Rico Branch) LLC](https://www.keypedia.com/companies/msd-international-gmbh-puerto-rico-branch-llc/98d0fc68-f819-4431-899c-0483c3329777)
- [Ascent Pharmaceuticals Inc](https://www.keypedia.com/companies/ascent-pharmaceuticals-inc/a6df28ee-9e4e-4fae-8eed-dbe5eb870593)
- [Sciegen Pharmaceuticals Inc](https://www.keypedia.com/companies/sciegen-pharmaceuticals-inc/814ff2a4-e264-431f-bffa-9932abda619d)
- [Jubilant Generics Limited](https://www.keypedia.com/companies/jubilant-generics-limited/0e33a821-8bc0-4f36-9264-5a108f087380)

## Related Officers

- [Patric C. Klotzbuecher](https://www.keypedia.com/people/patric-c-klotzbuecher/cbb2e6b5-b001-457e-9073-33535f02926e)
- [Director](https://www.keypedia.com/people/francis-godwin/1556d203-d47c-4744-af37-2591a163149e)
- [Dipesh K. Shah](https://www.keypedia.com/people/dipesh-k-shah/d4df4040-13d1-477b-8c21-4c8e5b3fc5b9)
